Disitamab vedotin plus toripalimab improved progression-free survival and overall survival when compared to chemotherapy.

Background More than 429,000 patients worldwide are diagnosed with bladder cancer each year and muscle-invasive bladder cancer has an especially poor outcome. The median age at diagnosis is over 70 ...

1. Huang J. Disitamab vedotin plus tislelizumab as nephron-sparing therapy for high-risk upper tract urothelial carcinoma: The phase II DISTINCT-I trial. Presented at: ESMO 2025 Congress; October ...

ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.

Loqtorzi significantly improved progression-free and overall survival in HER2-expressing advanced urothelial carcinoma compared to chemotherapy. The study demonstrated a higher overall response rate ...

Patients with upper tract urothelial carcinoma (UTUC) and urinary tract stone history are a high-risk subgroup requiring greater surveillance.

Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes. Among patients with advanced urothelial carcinoma who ...

Feasibility and efficacy of cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer in older patients: A retrospective French GETUG study. This is an ASCO Meeting Abstract from the ...

Urothelium is the term for the mucous membrane that lines the urinary tract. This includes the renal pelvis, ureter, urinary bladder and the upper part of the urethra. In the vast majority of cases, ...

Using the Shiny method, a more nuanced approach to meta-analysis, investigators determined that enfortumab vedotin plus pembrolizumab outperforms chemotherapy-based regimens for urothelial carcinoma.

Conducting Clinical Research in Low Research Resource Countries: Lessons Learned From the International Registry of Men With Advanced Prostate Cancer Study in Nigeria A retrospective study was ...

Urothelial carcinoma, a common urinary system malignancy with marked heterogeneity, leads to significantly varied clinical outcomes among patients, creating major treatment challenges. HER2, a key ...